

Medtronic plc  
Form 8-A12B  
March 07, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES**  
**PURSUANT TO SECTION 12(b) OR 12(g) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**

**Medtronic Global Holdings S.C.A.**

**(Exact name of registrant as specified in its charter)**

**Luxembourg**  
**(State or other jurisdiction of incorporation or**  
**organization)**

**98-1202865**  
**(I.R.S. Employer Identification No.)**

**3b, boulevard Prince Henri**

**Luxembourg City, 1724**

**Luxembourg**  
(Address of principal executive offices)

(Zip Code)

**Medtronic Public Limited Company**  
(Exact name of registrant as specified in its charter)

**Ireland**  
(State or other jurisdiction of incorporation or organization)

**98-1183488**  
(I.R.S. Employer Identification No.)

**20 On Hatch, Lower Hatch Street**

**Dublin 2**

**Ireland**

(Zip Code)

**Medtronic, Inc.**  
(Exact name of registrant as specified in its charter)

**Minnesota**  
(State or other jurisdiction of incorporation or organization)

**41-0793183**  
(I.R.S. Employer Identification No.)

**710 Medtronic Parkway**

**Minneapolis, Minnesota**  
(Address of principal executive offices)

**55432**  
(Zip Code)

**Securities to be registered pursuant to Section 12(b) of the Act:**

<b>Title of each class to be so registered</b>	<b>Name of each exchange on which each class is to be registered</b>
<b>Floating Rate Senior Notes due 2021</b>	<b>New York Stock Exchange LLC</b>
<b>0.000% Senior Notes due 2021</b>	
<b>0.375% Senior Notes due 2023</b>	
<b>1.125% Senior Notes due 2027</b>	
<b>1.625% Senior Notes due 2031</b>	
<b>2.250% Senior Notes due 2039</b>	

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.

**Securities Act registration statement file number to which this form relates:**

**333-215895**

**(If applicable)**

**Securities to be registered pursuant to Section 12(g) of the Act:**

**None**

## INFORMATION REQUIRED IN REGISTRATION STATEMENT

Medtronic Global Holdings, S.C.A. ( Medtronic Luxco ), Medtronic Public Limited Company ( Medtronic plc ), and Medtronic, Inc. ( Medtronic, Inc. and together with Medtronic Luxco and Medtronic plc, the Registrants ) have filed with the Securities and Exchange Commission (the Commission ) pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the Securities Act ), a prospectus supplement, dated March 4, 2019 (the Prospectus Supplement ), and the accompanying prospectus, dated February 3, 2017 (the Base Prospectus ). The Prospectus Supplement relates to the issuance and sale by Medtronic Luxco of 500,000,000 principal amount of its Floating Rate Senior Notes due 2021 (the Floating Rate Notes ), 1,500,000,000 principal amount of its 0.000% Senior Notes due 2021 (the 2021 Notes ), 1,500,000,000 principal amount of its 0.375% Senior Notes due 2023 (the 2023 Notes ), 1,500,000,000 principal amount of its 1.125% Senior Notes due 2027 (the 2027 Notes ), 1,000,000,000 principal amount of its 1.625% Senior Notes due 2031 (the 2031 Notes ) and 1,000,000,000 principal amount of its 2.250% Senior Notes due 2039 (the 2039 Notes ), and together with the Floating Rate Notes, the 2021 Notes, the 2023 Notes, the 2027 Notes, and the 2031 Notes, the Notes ). The Notes will be fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc. The Base Prospectus forms a part of the Registrants Registration Statement on Form S-3 (File No. 333-215895), filed with the Commission on February 6, 2017.

### Item 1. Description of Registrant s Securities to be Registered.

The information required by this item is incorporated by reference to the information contained in the sections captioned Description of Notes in the Prospectus Supplement and Description of Debt Securities of Medtronic Global Holdings S.C.A. in the Base Prospectus. Copies of such descriptions will be filed with the New York Stock Exchange.

### Item 2. Exhibits.

#### Exhibit

No.	Description
4.1	Base Indenture, dated as of as March 28, 2017, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc and Wells Fargo Bank, N.A., as trustee ( Medtronic Luxco Senior Indenture ) (incorporated by reference to Exhibit 4.1 to Medtronic plc s Form 8-K, filed on March 28, 2017)
4.2	Second Supplemental Indenture to Medtronic Luxco Senior Indenture, dated as of March 7, 2019 between Medtronic plc, Wells Fargo Bank, N.A. as trustee, and Elavon Financial Services DAC, UK Branch (incorporated by reference to Exhibit 4.1 to Medtronic plc s Form 8-K, filed on March 7, 2019)
4.3	Agency Agreement, dated as of March 7, 2019, between Medtronic Luxco, Wells Fargo Bank, N.A., as trustee, Elavon Financial Services DAC, UK Branch, as paying agent, Elavon Financial Services DAC, UK Branch, as calculation agent, and Elavon Financial Services DAC, as transfer agent and registrar (incorporated by reference to Exhibit 4.2 to Medtronic plc s Form 8-K, filed on March 7, 2019)

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, each Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

**MEDTRONIC GLOBAL HOLDINGS  
S.C.A.**, a Luxembourg corporate partnership  
limited by shares (*société en commandite par  
actions*) represented by Medtronic Global  
Holdings GP S.à.r.l. its General Partnership, in  
turn acting by

By: /s/ Erik De Gres  
Name: Erik De Gres  
Title: Managing Director

**MEDTRONIC PUBLIC LIMITED  
COMPANY**

By: /s/ Karen L. Parkhill  
Name: Karen L. Parkhill  
Title: Executive Vice President  
and Chief Financial Officer

**MEDTRONIC, INC.**

By: /s/ Karen L. Parkhill  
Name: Karen L. Parkhill  
Title: Executive Vice President  
and Chief Financial Officer

Dated: March 7, 2019